Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRγδ T Cells and Blinatumomab in Haploidentical HCT for Relapsed Hematologic Malignancies
NCT02790515Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 2016
- Primary completion
- Jul 2025
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab and TCR alpha/beta and CD45RA depleted hematopoietic stem cells in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myeloid sarcoma (MS) and 4 more, sponsored by St. Jude Children's Research Hospital. Primary endpoint: Number of patients engrafted by day +30 post-transplant at 30 days. Started Jul 2016; status: active, not recruiting.
02
Drugs
blinatumomabTCR alpha/beta and CD45RA depleted hematopoietic stem cells
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myeloid sarcoma (MS)chronic myeloid leukemia (CML)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT02790515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02790515.